10312 Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices 

behalf of, Sharp, or any of its affiliated 

companies, parents, subsidiaries, 

licensees, contractors, or other related 

business entities, or successors or 

assigns; and (2) cease and desist orders 

prohibiting Sharp Electronics Corp. and 

Sharp Electronics Manufacturing Co. 

from conducting any of the following 

activities in the United States: 

Importing, selling, marketing, 

advertising, distributing, offering for 

sale, transferring (except for 

exportation), and soliciting U.S. agents 

or distributors for, LCD devices, 

including display panels and modules, 

and LCD televisions or professional 

displays containing the same that are 

covered by claims 7 or 8 of the ‘344 

patent. 

On February 12, 2010, complainant 

Samsung and respondent Sharp filed a 

joint petition to rescind the remedial 

orders under Commission Rule 

210.76(a)(1) on the basis of a settlement 

agreement between the parties. The 

parties asserted that their settlement 

agreement constitutes ‘‘changed 

conditions of fact or law’’ sufficient to 

justify rescission of the order under 

Commission Rule 210.76(a)(1), 19 CFR 

210.76(a)(1). The IA did not oppose the 

joint petition. 

Having reviewed the parties’ 

submissions, the Commission has 

determined that the settlement 

agreement satisfies the requirement of 

Commission Rule 210.76(a)(1), 19 CFR 

210.76(a)(1), that there be changed 

conditions of fact or law. The 

Commission therefore has issued an 

order rescinding the limited exclusion 

order and cease and desist orders 

previously issued in this investigation. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930 (19 U.S.C. 1337) and section 

210.76(a)(1) of the Commission’s Rules 

of Practice and Procedure (19 CFR 

210.76(a)(1)). 

Issued: March 1, 2010. 

By order of the Commission. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. 2010–4692 Filed 3–4–10; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated October 20, 2009, and 

published in the Federal Register on 

October 28, 2009 (74 FR 55583), 

Formulation Technologies LLC., 11501 

Domain Drive, Suite 130, Austin, Texas 

78758, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Fentanyl (9801), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import the 

listed controlled substance for analytical 

characterization, secondary packaging, 

and for distribution to clinical trial sites. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Formulation Technologies LLC., to 

import the basic class of controlled 

substance is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971, at this time. DEA has 

investigated Formulation Technologies 

LLC., to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: February 26, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4722 Filed 3–4–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances 

Notice of Registration 

By Notice dated November 23, 2009, 

and published in the Federal Register 

on December 2, 2009 (74 FR 63155), 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the basic 

classes of controlled substances listed in 

schedule II: 

Drug Schedule 

Opium, raw (9600) ....................... II 

Poppy Straw Concentrate (9670) II 

The company plans to import the 

basic classes of controlled substances 

for manufacture of active 

pharmaceutical ingredients for sale to 

its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Cambrex Charles City, Inc. to import the 

basic classes of controlled substances is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Cambrex Charles City, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: February 26, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4773 Filed 3–4–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances 

Notice of Registration 

By Notice dated October 21, 2009, and 

published in the Federal Register on 

October 28, 2009 (74 FR 55584), Hospira 

Inc., 1776 North Centennial Drive, 

McPherson, Kansas 67460–1247, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of 

Remifentanil (9739), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import 

Remifentanil for use in dosage form 

manufacturing. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Hospira Inc. to import the basic class of 

controlled substance is consistent with 

the public interest, and with United 

States obligations under international 


erowe on DSK5CLS3C1PROD with NOTICES